Europe and Middle East & Africa Vaginal Panel Testing Market: Introduction
According to the report, the vaginal panel testing market in EMEA was valued at US$ 117.5 Mn in 2020 and is projected to expand at a CAGR of 3.9% from 2021 to 2031. Vaginal panel testing is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginalis. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA. Vaginal panel is intended to assist in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S...
Accurate Diagnosis of Vaginal Infections
Accurate screening & detection of bacterial, yeast, fungi, and viral samples in clinical pathology using vaginal testing panels has allowed less turnaround time due to their lower chances of producing false positive results due to broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of results. This will help in more women undergoing diagnostic tests for vaginal testing, which, in turn, increases the number of diagnostic vaginal testing procedures.
Moreover, incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, more women are likely to undergo molecular diagnostic tests for vaginal infections, which is projected to drive the vaginal testing panels market in EMEA.
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=c...
Molecular Nucleic Acid Amplification Test (NAAT) to Lead Europe and Middle East & Africa Vaginal Panel Testing Market
In terms of type, the vaginal panel testing market in EMEA has been bifurcated into direct molecular DNA probe and molecular nucleic acid amplification test (NAAT). The molecular nucleic acid amplification test segment held major market share in 2020. Increase in usage of molecular nucleic acid amplification test (NAAT) for the diagnosis & screening of vaginal infections due to high accuracy & sensitivity in production of results is anticipated to propel the segment in the near future. Nucleic acid amplification tests (NAATs), such as PCR, can identify as little as one organism in a sample. These employ techniques that multiply a nucleic acid sequence enzymatically, resulting in the synthesis of billions of copies in a short time.
Bacterial Vaginosis to be Key Application Area
Based on application, the vaginal panel testing market in EMEA has been classified into bacterial vaginosis, vulvovaginal candidiasis, chlamydia, gonorrhoea, trichomoniasis, and others. Bacterial vaginosis (BV) is the most prevalent cause of vaginal discharge in women of reproductive age. Although not a sexually transmitted disease, sexual activity is a risk factor for its transmission. It is linked to changes in vaginal ecology, including a reduction in the vaginal lactobacilli population and an overgrowth of anaerobes and G. vaginalis.
Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=E...
In women of reproductive age, bacterial vaginosis is a prevalent vaginal microbiota dysbiosis. The prevalence of bacterial vaginosis in Europe stands at around 4% to 14%.
Hospitals to be Major End-user
In terms of end-user, the vaginal panel testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others. Increase in focus on providing quality care, rise in emphasis on early diagnostics of vaginal infections, and surge in number of well-equipped specialty hospitals are expected to augment the segment during the forecast period. The growth of the segment can be ascribed to rise in prevalence of infectious diseases such as vaginal infections and increase in awareness about these infections among people.
Europe to Dominate Europe and Middle East & Africa Vaginal Panel Testing Market
Europe dominated the vaginal panel testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in investment in health care infrastructure, and surge in demand for better healthcare facilities fuel the growth of the vaginal testing panel market in Europe. Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. The growth of the market in the country can be attributed to increase in research activities, rise in government funding for research & development, and surge in number of biotechnology companies.
Competition Landscape
The vaginal panel testing market in EMEA is fragmented due to the presence of a large number of leading players. Key players operating in the market include Abbott Laboratories, Atrida, Becton, Dickenson and Company, Cepheid (Danaher Corporation), F. Hoffmann-La Roche Ltd., Hologic, Inc., Laboratory Corporation of America Holdings, Mologic Ltd., QIAGEN, Quest Diagnostics Incorporated, and Quidel Corporation.